Shifting Towards Empagliflozin First-Line Therapy in Glycogen Storage Disease Type Ib: A Nationwide Real-World Study
A diabetes drug given first works better than standard treatments for a rare metabolic disorder, cutting infections and hospitalizations in children.
In a nationwide real-world study of 42 GSD Ib patients, empagliflozin as first-line monotherapy delivered clinically superior outcomes compared to G-CSF or no treatment across pediatric patients, including reduced infections, hospitalizations, and inflammatory bowel disease. This validates SGLT2 inhibitor repurposing as a transformative first-line strategy for this ultra-rare, life-limiting metabolic disorder with high unmet need.
What the study was
- Study design
- Nationwide retrospective cohort study with four treatment comparator groups
- Population
- GSD Ib patients (pediatric and adult), nationwide Turkey registry
- Sample size
- 42
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of inherited metabolic disease
Why it surfaced
Nationwide real-world study demonstrating empagliflozin first-line monotherapy superiority over G-CSF in GSD Ib (ultra-rare, life-limiting disease). SGLT2i repurposing with direct, clinically meaningful benefit in a disease with very limited treatment options. NOVEL_TREATMENT flag triggers HIGH priority per schema rules despite triage_score 7.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.